Trade Evotec AG - EVT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.075 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022085% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000137% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | Germany | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Evotec SE ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 12.665 |
Open* | 12.88 |
1-Year Change* | -28.7% |
Day's Range* | 12.84 - 13.285 |
52 wk Range | 14.10-24.44 |
Average Volume (10 days) | 1.22M |
Average Volume (3 months) | 12.25M |
Market Cap | 2.58B |
P/E Ratio | -100.00K |
Shares Outstanding | 176.94M |
Revenue | 820.80M |
EPS | -0.54 |
Dividend (Yield %) | N/A |
Beta | 0.98 |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 18, 2024 | 13.055 | 0.395 | 3.12% | 12.660 | 13.305 | 12.660 |
Mar 15, 2024 | 12.665 | -0.310 | -2.39% | 12.975 | 13.015 | 12.560 |
Mar 14, 2024 | 13.110 | 0.160 | 1.24% | 12.950 | 13.445 | 12.925 |
Mar 13, 2024 | 12.920 | -0.360 | -2.71% | 13.280 | 13.415 | 12.880 |
Mar 12, 2024 | 13.215 | 0.130 | 0.99% | 13.085 | 13.330 | 12.980 |
Mar 11, 2024 | 13.015 | 0.085 | 0.66% | 12.930 | 13.045 | 12.665 |
Mar 8, 2024 | 12.975 | -0.015 | -0.12% | 12.990 | 13.075 | 12.690 |
Mar 7, 2024 | 13.045 | 0.065 | 0.50% | 12.980 | 13.170 | 12.870 |
Mar 6, 2024 | 13.035 | 0.200 | 1.56% | 12.835 | 13.110 | 12.745 |
Mar 5, 2024 | 12.930 | -0.330 | -2.49% | 13.260 | 13.425 | 12.750 |
Mar 4, 2024 | 13.255 | -0.615 | -4.43% | 13.870 | 13.975 | 13.255 |
Mar 1, 2024 | 13.895 | 0.330 | 2.43% | 13.565 | 13.925 | 13.535 |
Feb 29, 2024 | 13.670 | -0.200 | -1.44% | 13.870 | 13.970 | 13.470 |
Feb 28, 2024 | 13.885 | -0.215 | -1.52% | 14.100 | 14.175 | 13.765 |
Feb 27, 2024 | 14.075 | 0.235 | 1.70% | 13.840 | 14.245 | 13.620 |
Feb 26, 2024 | 13.865 | -0.010 | -0.07% | 13.875 | 14.040 | 13.625 |
Feb 23, 2024 | 13.935 | 0.295 | 2.16% | 13.640 | 14.000 | 13.475 |
Feb 22, 2024 | 13.665 | -0.025 | -0.18% | 13.690 | 13.800 | 13.475 |
Feb 21, 2024 | 13.500 | -0.055 | -0.41% | 13.555 | 13.640 | 13.205 |
Feb 20, 2024 | 13.670 | 0.030 | 0.22% | 13.640 | 13.710 | 13.465 |
Evotec AG Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, June 19, 2024 | ||
Time (UTC) 10:59 | Country DE
| Event Evotec SE Annual Shareholders Meeting Evotec SE Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 751.448 | 618.034 | 500.924 | 446.437 | 375.405 |
Revenue | 751.448 | 618.034 | 500.924 | 446.437 | 375.405 |
Cost of Revenue, Total | 577.383 | 466.491 | 375.181 | 313.546 | 263.389 |
Gross Profit | 174.065 | 151.543 | 125.743 | 132.891 | 112.016 |
Total Operating Expense | 724.824 | 588.901 | 452.368 | 383.843 | 297.942 |
Selling/General/Admin. Expenses, Total | 156.19 | 105.445 | 77.205 | 66.546 | 57.012 |
Research & Development | 76.642 | 72.2 | 63.945 | 58.432 | 35.619 |
Unusual Expense (Income) | -5.774 | 12.546 | 3.244 | 11.919 | -11.036 |
Other Operating Expenses, Total | -79.617 | -67.781 | -67.207 | -66.6 | -47.042 |
Operating Income | 26.624 | 29.133 | 48.556 | 62.594 | 77.463 |
Interest Income (Expense), Net Non-Operating | -179.854 | 208.106 | -22.925 | -6.102 | -5.602 |
Other, Net | -0.727 | -0.259 | 0.209 | 0.07 | 0.138 |
Net Income Before Taxes | -153.957 | 236.98 | 25.84 | 56.562 | 71.999 |
Net Income After Taxes | -175.655 | 215.51 | 6.278 | 37.228 | 84.056 |
Minority Interest | 0 | 0 | 0 | 0.844 | 0.116 |
Net Income Before Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Net Income | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Income Available to Common Excl. Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Income Available to Common Incl. Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Diluted Net Income | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Diluted Weighted Average Shares | 176.674 | 166.406 | 153.752 | 149.726 | 147.482 |
Diluted EPS Excluding Extraordinary Items | -0.99423 | 1.29509 | 0.04083 | 0.25428 | 0.57073 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -1.01547 | 1.36365 | 0.05455 | 0.30667 | 0.52209 |
Dilution Adjustment | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 170.279 | 213.556 | 240.689 | 173.884 | 172.203 |
Revenue | 170.279 | 213.556 | 240.689 | 173.884 | 172.203 |
Cost of Revenue, Total | 123.956 | 160.319 | 158.233 | 145.464 | 141.308 |
Gross Profit | 46.323 | 53.237 | 82.456 | 28.42 | 30.895 |
Total Operating Expense | 206.567 | 201.041 | 197.229 | 187.413 | 175.973 |
Selling/General/Admin. Expenses, Total | 45.609 | 42.583 | 46.332 | 42.462 | 35.83 |
Research & Development | 12.377 | 18.486 | 21.322 | 18.482 | 18.725 |
Other Operating Expenses, Total | 24.625 | -20.347 | -22.884 | -18.995 | -19.89 |
Operating Income | -36.288 | 12.515 | 43.46 | -13.529 | -3.77 |
Interest Income (Expense), Net Non-Operating | 5.261 | -6.203 | -60.362 | -29.806 | -20.131 |
Other, Net | 10.59 | -12.527 | -0.622 | -0.029 | -0.435 |
Net Income Before Taxes | -20.437 | -6.215 | -17.524 | -43.364 | -24.336 |
Net Income After Taxes | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Net Income Before Extra. Items | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Net Income | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Income Available to Common Excl. Extra. Items | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Income Available to Common Incl. Extra. Items | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Diluted Net Income | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Diluted Weighted Average Shares | 176.936 | 176.936 | 176.589 | 176.703 | 176.703 |
Diluted EPS Excluding Extraordinary Items | -0.08438 | -0.07855 | -0.15404 | -0.26754 | -0.1581 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -0.08438 | -0.07855 | -0.17529 | -0.26754 | -0.1581 |
Unusual Expense (Income) | -5.774 | 0 | 0 | ||
Minority Interest | 0 | ||||
Total Adjustments to Net Income | -0.001 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1073.67 | 1100.94 | 658.844 | 469.53 | 249.769 |
Cash and Short Term Investments | 729.983 | 858.498 | 492.634 | 321.662 | 149.879 |
Cash & Equivalents | 415.155 | 699.326 | 422.58 | 277.034 | 109.055 |
Short Term Investments | 314.828 | 159.172 | 70.054 | 44.628 | 40.824 |
Total Receivables, Net | 256.737 | 176.754 | 122.221 | 117.844 | 74.772 |
Accounts Receivable - Trade, Net | 199.169 | 150.692 | 91.612 | 93.702 | 58.851 |
Total Inventory | 29.825 | 25.793 | 13.585 | 10.749 | 5.66 |
Prepaid Expenses | 40.178 | 19.21 | 9.258 | 9.166 | 8.451 |
Other Current Assets, Total | 16.948 | 20.685 | 21.146 | 10.109 | 11.007 |
Total Assets | 2257.25 | 2235.16 | 1462.34 | 1180.91 | 771.883 |
Property/Plant/Equipment, Total - Net | 650.201 | 484.597 | 337.297 | 239.229 | 90.519 |
Property/Plant/Equipment, Total - Gross | 920.81 | 686.086 | 481.879 | 350.415 | 164.143 |
Accumulated Depreciation, Total | -270.609 | -201.489 | -144.582 | -111.186 | -73.624 |
Goodwill, Net | 274.819 | 257.569 | 247.37 | 255.919 | 220.791 |
Intangibles, Net | 23.819 | 30.851 | 98.036 | 116.994 | 122.989 |
Long Term Investments | 150.332 | 287.009 | 59.021 | 41.252 | 28.99 |
Note Receivable - Long Term | 70.293 | 55.966 | 36.485 | 22.718 | 14.601 |
Other Long Term Assets, Total | 14.112 | 18.229 | 25.284 | 35.27 | 44.224 |
Total Current Liabilities | 337.706 | 324.516 | 208.459 | 178.955 | 196.275 |
Accounts Payable | 97.277 | 72.598 | 42.549 | 31.319 | 31.137 |
Accrued Expenses | 47.49 | 33.983 | 34.728 | 29.174 | 25.67 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 16.381 | 50.609 | 30.008 | 20.731 | 56.919 |
Other Current Liabilities, Total | 176.558 | 167.326 | 101.174 | 97.731 | 82.549 |
Total Liabilities | 1070.06 | 857.476 | 737.881 | 703.883 | 347.879 |
Total Long Term Debt | 490.293 | 462.308 | 461.957 | 442.368 | 57.546 |
Long Term Debt | 328.295 | 326.344 | 331.019 | 324.886 | 54.68 |
Capital Lease Obligations | 161.998 | 135.964 | 130.938 | 117.482 | 2.866 |
Deferred Income Tax | 18.524 | 17.688 | 20.399 | 21.199 | 21.517 |
Minority Interest | 0 | 0 | 0 | 0 | 0.876 |
Other Liabilities, Total | 223.54 | 52.964 | 47.066 | 61.361 | 71.665 |
Total Equity | 1187.18 | 1377.69 | 724.456 | 477.029 | 424.004 |
Common Stock | 176.953 | 176.608 | 163.915 | 150.903 | 149.063 |
Additional Paid-In Capital | 1440.01 | 1430.14 | 1030.7 | 786.865 | 783.154 |
Retained Earnings (Accumulated Deficit) | -392.377 | -216.421 | -432.639 | -441.177 | -481.013 |
Unrealized Gain (Loss) | -21.113 | 3.053 | 4.26 | 4.565 | 6.002 |
Other Equity, Total | -16.289 | -15.691 | -41.782 | -24.127 | -33.202 |
Total Liabilities & Shareholders’ Equity | 2257.25 | 2235.16 | 1462.34 | 1180.91 | 771.883 |
Total Common Shares Outstanding | 176.703 | 176.358 | 163.665 | 150.653 | 148.813 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 939.198 | 1026.45 | 1073.67 | 1095.82 | |
Cash and Short Term Investments | 619.18 | 632.973 | 729.983 | 828.795 | |
Cash & Equivalents | 499.366 | 459.752 | 415.155 | 463.913 | |
Short Term Investments | 119.814 | 173.221 | 314.828 | 364.882 | |
Total Receivables, Net | 219.371 | 291.301 | 256.737 | 187.997 | |
Accounts Receivable - Trade, Net | 161.105 | 228.955 | 199.169 | 140.631 | |
Total Inventory | 31.906 | 32.612 | 29.825 | 30.874 | |
Prepaid Expenses | 68.741 | 69.563 | 57.126 | 48.15 | |
Total Assets | 2254.51 | 2301.22 | 2257.25 | 2262.66 | |
Property/Plant/Equipment, Total - Net | 763.899 | 721.136 | 650.201 | 600.499 | |
Goodwill, Net | 274.819 | 278.417 | |||
Intangibles, Net | 291.055 | 292.612 | 23.819 | 25.736 | |
Long Term Investments | 151.62 | 160.842 | 150.332 | 189.245 | |
Note Receivable - Long Term | 98.685 | 88.8 | 70.293 | 56.911 | |
Other Long Term Assets, Total | 10.052 | 11.382 | 14.112 | 16.039 | |
Total Current Liabilities | 434.045 | 488.107 | 337.706 | 340.802 | |
Accounts Payable | 96.774 | 106.038 | 97.277 | 83.965 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
Current Port. of LT Debt/Capital Leases | 144.287 | 151.638 | 16.381 | 14.108 | |
Other Current Liabilities, Total | 192.984 | 230.431 | 224.048 | 242.729 | |
Total Liabilities | 1113.69 | 1126.93 | 1070.06 | 1034.14 | |
Total Long Term Debt | 444.455 | 382.509 | 490.293 | 477.984 | |
Long Term Debt | 444.455 | 382.509 | 328.295 | 326.776 | |
Capital Lease Obligations | 161.998 | 151.208 | |||
Deferred Income Tax | 18.603 | 19.13 | 18.524 | 17.179 | |
Other Liabilities, Total | 216.587 | 237.188 | 223.54 | 198.173 | |
Total Equity | 1140.82 | 1174.29 | 1187.18 | 1228.53 | |
Common Stock | 177.186 | 177.186 | 176.953 | 176.953 | |
Additional Paid-In Capital | 1446.47 | 1445.36 | 1440.01 | 1437.55 | |
Retained Earnings (Accumulated Deficit) | -482.836 | -448.256 | -392.377 | -364.631 | |
Other Equity, Total | -16.289 | -21.348 | |||
Total Liabilities & Shareholders’ Equity | 2254.51 | 2301.22 | 2257.25 | 2262.66 | |
Total Common Shares Outstanding | 176.936 | 176.936 | 176.703 | 176.703 | |
Unrealized Gain (Loss) | -21.113 | ||||
Minority Interest | 0 | 0 | 0 | 0 | |
Other Current Assets, Total | 0.001 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -175.655 | 215.51 | 6.252 | 37.228 | 84.056 |
Cash From Operating Activities | 203.106 | 122.237 | 44.721 | 42.216 | 156.24 |
Cash From Operating Activities | 72.677 | 55.596 | 42.122 | 36.456 | 19.288 |
Amortization | 8.982 | 12.012 | 13.936 | 12.349 | 12.005 |
Deferred Taxes | 7.722 | 5.066 | 7.49 | 6.706 | -26.117 |
Non-Cash Items | 195.391 | -165.371 | 23.865 | 24.342 | 0.364 |
Cash Taxes Paid | 18.5 | -6.028 | 9.796 | 2.417 | 3.596 |
Cash Interest Paid | 9.798 | 5.429 | 3.465 | 4.49 | 2.279 |
Changes in Working Capital | 93.989 | -0.576 | -48.944 | -74.865 | 66.644 |
Cash From Investing Activities | -415.823 | -243.855 | -155.089 | -86.634 | -39.13 |
Capital Expenditures | -181.354 | -118.943 | -99.072 | -31.905 | -27.867 |
Other Investing Cash Flow Items, Total | -234.469 | -124.912 | -56.017 | -54.729 | -11.263 |
Cash From Financing Activities | -52.414 | 398.43 | 246.409 | 211.263 | -77.764 |
Financing Cash Flow Items | |||||
Issuance (Retirement) of Stock, Net | 0.699 | 404.322 | 251.564 | 1.901 | 1.578 |
Issuance (Retirement) of Debt, Net | -53.113 | -5.892 | -5.155 | 209.362 | -79.342 |
Foreign Exchange Effects | -19.04 | -0.066 | 9.505 | 1.134 | 2.692 |
Net Change in Cash | -284.171 | 276.746 | 145.546 | 167.979 | 42.038 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -175.655 | -148.454 | -101.179 | -73.242 | 215.51 |
Cash From Operating Activities | 203.106 | 236.633 | 240.607 | 63.618 | 122.237 |
Changes in Working Capital | 378.761 | 385.087 | 341.786 | 136.86 | -93.273 |
Cash From Investing Activities | -415.823 | -435.034 | -206.857 | -95.732 | -243.855 |
Capital Expenditures | -181.354 | -157.21 | -81.371 | -42.921 | -118.943 |
Other Investing Cash Flow Items, Total | -234.469 | -277.824 | -125.486 | -52.811 | -124.912 |
Cash From Financing Activities | -52.414 | -50.454 | -45.805 | -5.279 | 398.43 |
Issuance (Retirement) of Stock, Net | 0.699 | 0.355 | 0.7 | 0.345 | 404.322 |
Issuance (Retirement) of Debt, Net | -53.113 | -50.809 | -46.505 | -5.624 | -5.892 |
Foreign Exchange Effects | -19.04 | 13.442 | 9.721 | -1.445 | -0.066 |
Net Change in Cash | -284.171 | -235.413 | -2.334 | -38.838 | 276.746 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Novo Holdings A/S | Venture Capital | 9.8455 | 17444807 | -206374 | 2022-12-31 | LOW |
Government of Abu Dhabi | Government Agency | 6.5913 | 11678875 | 199342 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 5.0131 | 8882485 | 36011 | 2023-09-21 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.5645 | 6315718 | 2452073 | 2023-06-16 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.5926 | 4593730 | 1224 | 2023-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.2224 | 3937850 | 851779 | 2022-12-31 | LOW |
Brown Capital Management, LLC | Investment Advisor | 2.1752 | 3854173 | 18059 | 2023-03-31 | LOW |
Liontrust Investment Partners LLP | Investment Advisor | 2.0301 | 3597021 | -37024 | 2023-08-31 | LOW |
Allianz Global Investors GmbH | Investment Advisor | 1.84 | 3260133 | 10629 | 2023-08-31 | LOW |
Oetker (Roland) | Individual Investor | 1.639 | 2904146 | -5440854 | 2022-10-04 | LOW |
BlackRock Asset Management Deutschland AG | Investment Advisor | 1.5298 | 2710589 | -5722 | 2023-09-30 | LOW |
Franklin Equity Group | Investment Advisor | 1.2699 | 2250000 | 0 | 2023-09-30 | LOW |
Polar Capital LLP | Investment Advisor/Hedge Fund | 1.1488 | 2035438 | 0 | 2023-06-30 | LOW |
Deka Investment GmbH | Investment Advisor/Hedge Fund | 1.1055 | 1958807 | -3463 | 2023-09-30 | LOW |
California State Teachers Retirement System | Pension Fund | 1.0986 | 1946619 | 1704482 | 2022-06-30 | LOW |
Evotec SE Management | Corporation | 0.9987 | 1769527 | 0 | 2022-12-31 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.8748 | 1549952 | 4235 | 2023-09-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 0.7134 | 1263957 | -38325 | 2023-08-31 | LOW |
T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 0.6168 | 1092871 | -24740 | 2023-09-30 | LOW |
Lupus alpha Asset Management AG | Investment Advisor/Hedge Fund | 0.5858 | 1038000 | -105000 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Evotec Company profile
About Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Evotec SE revenues increased 20% to EUR431M. Net income increased from EUR5.8M to EUR247M. Revenues reflect EVT Execute segment increase of 22% to EUR329M, EVT Innovate segment increase of 36% to EUR101.9M, United States segment increase of 32% to EUR142.9M, Others segment increase of 30% to EUR47.5M, United Kingdom segment increase of 8% to EUR47.2M.
Industry: | Biotechnology & Medical Research (NEC) |
Essener Bogen 7
HAMBURG
HAMBURG 22419
DE
Income Statement
- Annual
- Quarterly
News
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?
UK banks will be in the spotlight in the week ahead as the European earnings season continues
16:38, 16 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com